Kingsview Wealth Management LLC bought a new position in ARK Genomic Revolution ETF (BATS:ARKG – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 206,252 shares of the company’s stock, valued at approximately $5,975,000. Kingsview Wealth Management LLC owned about 0.46% of ARK Genomic Revolution ETF as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Sunbelt Securities Inc. grew its stake in ARK Genomic Revolution ETF by 734.3% in the 3rd quarter. Sunbelt Securities Inc. now owns 1,118 shares of the company’s stock worth $31,000 after buying an additional 984 shares in the last quarter. AlphaCore Capital LLC purchased a new position in ARK Genomic Revolution ETF in the 4th quarter worth approximately $39,000. Strategic Wealth Investment Group LLC purchased a new position in ARK Genomic Revolution ETF in the 2nd quarter worth approximately $38,000. Allworth Financial LP grew its stake in ARK Genomic Revolution ETF by 39.9% in the 4th quarter. Allworth Financial LP now owns 2,061 shares of the company’s stock worth $60,000 after buying an additional 588 shares in the last quarter. Finally, Advisory Services Network LLC purchased a new position in ARK Genomic Revolution ETF in the 3rd quarter worth approximately $58,000.
ARK Genomic Revolution ETF Price Performance
ARKG stock opened at $34.64 on Friday. ARK Genomic Revolution ETF has a one year low of $20.46 and a one year high of $35.12. The firm has a 50 day simple moving average of $28.99 and a two-hundred day simple moving average of $29.46.
ARK Genomic Revolution ETF Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Featured Articles
- Five stocks we like better than ARK Genomic Revolution ETF
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
